This website is for Private Investors* only
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
- Obtains access to the information in a personal capacity;
- Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
- Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
- Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
- Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
- Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Tell us more
You are seeing these quotes based on previous browsing related to sectors such as
AstraZeneca (AZN)
8,555.00p
14:15 13/07/20
- 0.59% 50.00p
- Today's Low & High
- 8,438.00 / 8,589.00
- Open / Previous Close
- 8,548.00 / 8,505.00
- 52-week range
- 35.28% 2,231.00p
- Volume
- 662,017
- Market Cap(billion)
- £112.26b
8,561.00p
REAL TIME
- 15:34 13/07/20
- 0.81%
- 69.00p
Advertising
KEY FINANCIALS
| Latest | Forecast | |
|---|---|---|
| Div Yield | 2.6% | 2.6% |
| Div Cover | 0.4 | 1.4 |
| Op Mrgn | 12.0% | 24.8% |
| ROCE | 76.9% |
| Latest | Forecast | |
|---|---|---|
| P/E | 104.3 | 26.6 |
| PEG | -2.6 | 0.1 |
| Price / Revenue | 5.8 | 5.2 |
| Price / Book value | 9.7 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 10.4% | 3.0% |
| PBT | -22.3% | n/a |
| EPS | -39.4% | -5.3% |
| DPS | 0.0% | -1.2% |
KEY FUNDAMENTALS
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | 24,708.00 | 3,069.00 | $4.26 | 16.0 | -34.2 | 0% | $2.80 | 4.1% |
| 2016-12-31 | 23,002.00 | 3,552.00 | $4.31 | 12.7 | 10.8 | 1% | $2.80 | 5.1% |
| 2017-12-31 | 22,465.00 | 2,227.00 | $4.28 | 16.2 | -23.2 | -1% | $2.80 | 4.0% |
| 2018-12-31 | 22,090.00 | 1,993.00 | $1.70 | 44.0 | -0.7 | -60% | $2.80 | 3.7% |
| 2019-12-31 | 24,384.00 | 1,548.00 | $1.03 | 97.9 | -2.5 | -39% | $2.80 | 2.8% |
FORECAST
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | 21,112.00 | 5,242.82 | 315.02p | 26.6 | 0.1 | 286% | 221.20p | 2.6% |
| 2021-12-31 | 23,593.65 | 6,522.88 | 396.23p | 21.4 | 0.8 | 26% | 223.96p | 2.6% |
Latest Webfg News
| JP Morgan says 'pent-up' demand will be exhausted, stays 'overweight' on Tech and Healthcare Sharecast News | 13:42 |
|---|---|
| AstraZeneca stroke drug gets US green light Sharecast News | 09 Jul |
| AstraZeneca gets EU approval for Lynparza Sharecast News | 08 Jul |
Regulatory News
| Brilinta granted US FDA Priority Review for stroke | 09-Jul-20 07:07 |
|---|---|
| Lynparza approved in the EU for pancreatic cancer | 08-Jul-20 07:06 |
| Total Voting Rights | 01-Jul-20 15:01 |
| Director/PDMR Shareholding | 30-Jun-20 15:00 |
| Selumetinib granted Japan orphan drug designation | 30-Jun-20 07:08 |